Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children

Journal of Pediatric Endocrinology and Metabolism

Volumn 16, Issue 4, 2003, Pages 529-536

  Noguera, A ^a   Ros, J B ^a   Pavia C ^a   Alcover, E ^a   Valls, C ^b   Villaronga, M ^b   González, Enrique ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Bisphosphonate; Bone mineral density; Children; Chronic rheumatic diseases; Osteoporosis; Pamidronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; GLUCOCORTICOID; ONDANSETRON; PAMIDRONIC ACID; PARACETAMOL; SOMATOMEDIN C; ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; BIOCHEMISTRY; BONE RADIOGRAPHY; CHILD; CLINICAL ARTICLE; CLINICAL EXAMINATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DENSITOMETRY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; HYPERTHERMIA; LONG TERM CARE; MALE; NAUSEA AND VOMITING; PEDIATRICS; PUBERTY; RHEUMATIC DISEASE; VERTEBRA FRACTURE; BONE DENSITY; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFECT; KNEE; LUMBAR VERTEBRA; OSTEOPOROSIS; PRESCHOOL CHILD; RADIOGRAPHY; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; BONE DENSITY; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; KNEE JOINT; LUMBAR VERTEBRAE; MALE; OSTEOPOROSIS; TREATMENT OUTCOME;

EID: 0037928775     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2003.16.4.529     Document Type: Article

References (25)

1. Trapani S, Civinini R, Ermini M, Paci E, Falcini F. Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density. Rheumatol Int 1998; 18: 45-49.
2. Falcini F, Trapani S, Civinini R, Capone A, Ermini M, Bartolozzi G. The primary role of steroids on the osteoporosis in juvenile rheumatoid patients evaluated by dual energy X-ray absorptiometry. J Endocrinol Invest 1996; 19: 165-169.
3. González E. Osteoporosis infantil. In: González E. Manual de Reumatología Pediátrica. MRA s.l. Ed., 1999; 558-574.
4. Allgrove J. Bisphosphonates. Arch Dis Child 1997; 76: 73-75.
5. Shoemaker LR. Expanding role of bisphosphonate therapy in children. J Pediatr 1999; 134: 264-267.
6. Srivastava T, Alon US. Bisphosphonates: from grandparents to grandchildren. Clin Pediatr (Phila) 1999; 38: 687-702.
7. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202-211.
8. Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD, Suarez-Almazor ME. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999; 26: 1148-1157.
9. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15: 1006-1013.
10. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292-299.
11. Shaw NJ, Boivin CM, Crabtree NJ. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000; 83: 143-145.
12. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanque G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 147-952.
13. González E, Paviá C, Ros J, Villaronga M, Valls C, Escolà J. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001; 14: 529-533.
14. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998; 87: 64-68.
15. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997; 76: 266-283.
16. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85: 1846-1850.
17. De Schepper J, Pont S, Smitz J, De Coster D, Schots R, Otten J. Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcaemia in a 11-year-old boy. Eur J Pediatr 1999; 158: 765-768.
18. Lteif AN, Zimmermann D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics 1998; 102: 990-993.
19. Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, Sanctis C. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 2000; 89: 188-193.
20. Farran RP, Zaretsky E, Egeler RM. Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol 2001; 23: 54-56.
21. Zacharin M, Cundy T. Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. J Pediatr 2000; 137: 410-415.
22. Sellers E, Sharma A, Rodd C. The use of pamidronate in three children with renal disease. Pediatr Nephrol 1998; 12: 778-781.
23. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000; 43: 1960-1966.
24. Del Río L, Pavía J, Puchal R. Determinación de valores de normalidad de la masa ósea en columna lumbar; población española. II Symposium de la Sociedad Española de investigaciones óseas y metabolismo mineral (SEIOMN), Seville, Spain, May 1989.
25. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997; 131: 622-625.